Skip to main content

Protein Engineering Market Size to Reach USD 11.22 Billion in 2032 | Emergen Research

Increasing demand for protein-based drugs and rising investments by governments for protein engineering are driving the demand of the Protein Engineering market

Vancouver, Dec. 04, 2023 (GLOBE NEWSWIRE) — The global Protein Engineering Market is expected to reach USD 11.22 Billion by 2032, according to a new report by Emergen Research. The growth of this market can be attributed to the growing adoption of protein-based drugs compared to non-protein drugs. In addition, growing initiatives of the government, such as funding to encourage the research activities or increasing investments for the improvement of the healthcare infrastructure, are expected to drive the market’s growth.

Biopharmaceutical companies are extensively investing in the research and development of protein engineering to obtain cost-effective and efficient products with enhanced productivity and better patient outcomes.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/134

The pandemic has severely disrupted the supply chain and raw material supplies of the healthcare industry. With the spread of the COVID-19, there is a sudden increase in the need for the vaccine, resulting in increased research and development of the vaccine and drug testing. The government worldwide is investing a substantial amount of funds in the research and development. The Protein engineering market is expected to get significantly affected due to the numerous kinds of research carried out in this field.

Scope of Research

Report DetailsOutcome
Market size value in 2019USD 2.50 Billion
CAGR (2023 – 2032)12.7%
Revenue forecast in 2032USD 11.22 Billion
Base year for estimation2022
Historical data2019-2021
Forecast period2023-2032
Quantitative unitsVolume in Tons, Revenue in USD Thousand, and CAGR from 2023 to 2032
Report coverageRevenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments coveredTechnology, Protein Type, Product, End-User, region
Regional scopeNorth America; Europe; Asia Pacific; Central & South America; MEA
Country scopeU.S.; Canada; Mexico; U.K.; Germany; France; Italy; Spain; China; India; Japan; South Korea; Brazil; Saudi Arabia; South Africa; Turkey
Key companies profiledDanaher Corporation, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., Waters Corporations, Bio-Rad Laboratories, Merck KGaA, Bruker Corporation, Codexis, Inc., Genscript Biotech corporation and GE Healthcare
Customization scope10 hrs of free customization and expert consultation

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/134

MAJOR COMPANIES and Market Share Analysis

The Protein Engineering Market is moderately fragmented with a large number of small and medium-sized manufacturers, which account for a major part of the global share. The manufacturers are well-equipped with manufacturing facilities and are involved in several research & development activities. Some of the prominent players in this Market include:

  • Danaher Corporation
  • Thermo Fisher Scientific, Inc.
  • Agilent Technologies, Inc.
  • Waters Corporations
  • Bio-Rad Laboratories
  • Merck KGaA
  • Bruker Corporation
  • Codexis, Inc.
  • Genscript Biotech corporation
  • GE Healthcare

Strategic Development
In 2019, BioTek Instruments (US) was acquired by Agilent Technologies (US). The acquisition helped Agilent Technologies to strengthen its position in the immunotherapy and immune-oncology markets

Direct Order Can Be Placed Through This Link [Exclusive Copy] @ https://www.emergenresearch.com/select-license/134

Some Key Highlights from the Report

  • The Rational Protein Design segment dominated the market with a share of 53.2% in 2019 due to the increasing utilization of bioinformatics software for the analysis of protein.
  • The Monoclonal Antibodies accounted for the largest market share in 2019 due to the increasing investments in the R & D to develop therapeutically advanced monoclonal antibodies.
  • The Instruments dominated the market with a share of 56.3% in 2019 owing to the technological developments of the instruments.
  • The Biopharmaceutical Companies dominated the End-User segment due to the growing adoption of the advanced protein engineering processes.
  • The Asia-Pacific is expected to register the highest CAGR over the forecast period owing to the increasing initiatives of the governments of the developing economies to improve the healthcare infrastructure with advanced and cost-effective therapeutics.

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/protein-engineering-market

For the purpose of this report, Emergen Research has segmented the global Protein Engineering Market on the basis of Technology, Protein Type, Product, End-User, and region:

  • Technology Outlook (Revenue, USD Billion; 2019-2032)
    • Directed Evolution
    • Rational Protein Design
    • Hybrid approach
  • Protein Type Outlook (Revenue, USD Billion; 2019-2032)
    • Vaccines
    • Growth Hormones
    • Monoclonal Antibodies
    • Coagulation factors
    • Interferon
    • Colony Stimulating Factors
    • Others
  • Product Class Outlook (Revenue, USD Billion; 2019-2032)
    • Software & Services
    • Instruments
    • Consumables
  • End-User Class Outlook (Revenue, USD Billion; 2019-2032)
    • Contract Research Organizations
    • Academic Research Institutes
    • Biopharmaceutical Companies
  • Regional Outlook (Revenue, USD Billion; 2019-2032)
    • North America
      1. U.S.
      2. Canada
    • Europe
      1. Germany
      2. UK
      3. France
      4. BENELUX
      5. Rest of Europe
    • Asia Pacific
      1. China
      2. Japan
      3. South Korea
      4. Rest of APAC
    • Latin America
      1. Brazil
      2. Rest of LATAM
    • MEA
      1. Saudi Arabia
      2. UAE
      3. Rest of MEA

Curated Reports You Shouldn’t Miss: Dive In Now!

Light Detection and Ranging (LiDAR) Market, By Component (Laser Type, Scanner Type, Sensors, Navigation and Positioning System, and Others), By Technology, By Type, By Installation Type, by Range, By End-Use, and By Region Forecast to 2032.

Defibrillator Market By Type (Implantable Cardioverter Defibrillators and External Defibrillators), By Patient Type (Adult Patients and Pediatric Patients), By End-Use (Hospitals, Clinics, and Cardiac Centers), and By Region Forecast to 2030

Pain Management Devices Market By Type (Neurostimulation Devices, Infusion Pumps, and Ablation Devices), By Application (Neuropathic Pain, Cancer Pain, and Facial Pain & Migraine), By Mode of Purchase, and By Region Forecast to 2030.

Obstructive Hypertrophic Cardiomyopathy Market By Drug Class (Calcium Channel Blockers, Antiarrhythmic Agents, Beta Adrenergic Blocking Agents), By Route of Administration, By End-use, By Distribution Channel, By Region Forecast to 2030.

Allergy Diagnostics Market By Product & Service (Consumables, Instruments, Services), By Allergen (Inhaled Allergens, Food Allergens, Drug Allergens), By Test Type (In Vivo Tests, In Vitro Tests), By End-use, By Region, Forecast to 2030.

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.  

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: https://www.emergenresearch.com/

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Explore Our Japanese Version: Protein Engineering Market

Explore Our Blogs and Insights Section: https://www.emergenresearch.com/insights

Read our Press Release @ https://www.emergenresearch.com/press-release/global-protein-engineering-market

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.